Dr. Luis Guillermo Vargas Buonfiglio, MD

Dr. Vargas Buonfiglio practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Vargas Buonfiglio's NPI, 1164955779, was assigned on April 10, 2017. Dr. Vargas Buonfiglio holds Utah license 13440883-1205.

Dr. Vargas Buonfiglio's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Vargas Buonfiglio's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Vargas Buonfiglio is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Vargas Buonfiglio to 1 more hospital and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vargas Buonfiglio practices, 3 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Vargas Buonfiglio's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dmand AI has Dr. Vargas Buonfiglio's licenses on file in 2 states: Utah and Iowa.

CMS data shows 133 Medicare services from Dr. Vargas Buonfiglio across 3 procedure codes in 2024, for 82 Medicare patients. Medicare paid $14,550 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 82 Medicare patients who saw Dr. Vargas Buonfiglio in 2024. The largest group is 65 to 74, with 41 patients. 75% of them have high blood pressure, and 68% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.84, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vargas Buonfiglio's median patient age at 72, with 46% women.

In 2024, Dr. Vargas Buonfiglio wrote 107 Medicare Part D claims for 26 patients. 35% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $279,582 in total drug cost. In 2023, CMS named 40 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Vargas Buonfiglio for performance year 2024, reported as part of a group. Dr. Vargas Buonfiglio accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Dr. Vargas Buonfiglio from 1 drug or device company in 2025. Food and beverage make up the largest share, 86% of the total. Insmed, Inc. paid the most, $125.